A recent study found no difference in the risk of developing atrial fibrillation (AF) or major adverse cardiovascular events (MACE) associated with ustekinumab versus anti–tumor necrosis factor (anti-TNF) therapy in patients with psoriasis or psoriatic arthritis.
A recent study found no difference in the risk of developing atrial fibrillation (AF) or major adverse cardiovascular events (MACE) associated with ustekinumab versus anti—tumor necrosis factor (anti-TNF) therapy in patients with psoriasis or psoriatic arthritis.
However, the researchers said additional studies about potentially modifying treatment effects stratified by important risk factors may be warranted.
Evidence about the comparative cardiovascular CVD safety of current biologic treatments remains limited, even as a growing amount evidence indicates that there is an increased risk of cardiovascular disease among patients with psoriatic disease. Psoriatic disease is an independent risk factor for CVD with a 28% increase in risk of coronary heart disease, 6% to 12% increase in risk of stroke, and 20% increase in risk of a composite end point of myocardial infarction and stroke among patients with psoriatic disease compared with the general population.
Intervening early in psoriasis may control the systemic inflammation implicated in both diseases, researchers wrote. Psoriasis affects 125 million people worldwide. Newer biologics, such as ustekinumab, are more targeted to the inflammatory pathways involved in psoriasis. Ustekinumab works by blocking interleukin-17 and -23.
The study, published in JAMA Dermatology ,included data from a nationwide sample of 78,162 commercially insured patients in 2 databases (Optum and MarketScan) from September 25, 2009, through September 30, 2015. Patients were included if they were 18 years or older, had psoriasis or psoriatic arthritis, and began a ustekinumab or an anti-TNF therapy.
A total of 60,028 patients with psoriasis or psoriatic arthritis were included in the analysis (9071 using ustekinumab and 50,957 using an anti-TNF.). The mean age was 46 years in Optum and 47 in MarketScan; 29,495 (49.1%) were male. Overall crude incidence rates (reported per 1000 person-years) for AF were 5.0 (95% CI, 3.8-6.5) for ustekinumab initiators and 4.7 (95% CI, 4.2-5.2) for anti-TNF initiators. Incidence rates for MACE were 6.2 (95% CI, 4.9-7.8) for ustekinumab initiators and 6.1 (95% CI, 5.5-6.7) for anti-TNF initiators.
The combined adjusted hazard ratio for AF for those on ustekinumab was 1.08 (95% CI, 0.76-1.54); for MACE among those on ustekinumab, it was1.10 (95% CI, 0.80-1.52) compared with those on anti-TNF therapies.
The risks did not appear to substantially differ across the subgroups included in the study.
Reference
Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of ustekinumab vs tnf inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 2019;155(6):700-707. doi:10.1001/jamadermatol.2019.0001.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).